ReviewFrontiers in cardiovascular medicine2017
Cancer and Thrombotic Risk: The Platelet Paradigm.
Review in Frontiers in cardiovascular medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic Value and Clinicopathologic Features of Platelet Distribution Width in Cancer: A Meta-Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2018Pooled it
- Guided immunotherapy for residual solid tumor: integrating platelets and CAR T cells to reduce post-surgical recurrence.Biomarker research · 2026Review
- Article
- Interplay of genetic and clinical factors in cancer-associated thrombosis: Deciphering the prothrombotic landscape of colorectal cancer.World journal of gastroenterology · 2025Review
- KRAS-mutant colorectal cancer cell lines cause a prothrombotic state through the upregulation of thrombin: experimental study.Annals of medicine and surgery (2012) · 2024Article
- Pro-Tumorigenic and Thrombotic Activities of Platelets in Lung Cancer.International journal of molecular sciences · 2023Review
- NETworking with cancer: The bidirectional interplay between cancer and neutrophil extracellular traps.Cancer cell · 2023Review
- Identification of hub pathways and drug candidates in gastric cancer through systems biology.Scientific reports · 2022Article
- Venous Thromboembolism and Cancer: A Comprehensive Review from Pathophysiology to Novel Treatment.Biomolecules · 2022Review
- Trigger related outcomes of takotsubo syndrome in a cancer population.Frontiers in cardiovascular medicine · 2022Article
- Heparin and Derivatives for Advanced Cell Therapies.International journal of molecular sciences · 2021Review
- Cancer-Associated Thrombosis: A New Light on an Old Story.Diseases (Basel, Switzerland) · 2021Review
- Platelet Proteomes, Pathways, and Phenotypes as Informants of Vascular Wellness and Disease.Arteriosclerosis, thrombosis, and vascular biology · 2021Review
- Comparative analysis of enoxaparin versus rivaroxaban in the treatment of cancer associated venous thromboembolism: experience from a tertiary care cancer centre.Thrombosis journal · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Hematologic malignancies and solid tumors increase the risk of venous and arterial thrombosis and contribute greatly to patient morbidity and mortality. Thrombosis occurs when the intricate balance of circulating antithrombotic and prothrombotic blood elements are disrupted. In recent years, the interplay between paraneoplastic cells and platelets has become apparent, with a change in platelet phenotype causing dysregulated platelet activity. This review discusses mechanism of thrombosis in cancer, evidence for using drug therapy, and exciting research efforts to understand and hopefully control aberrant thrombotic events in patients with cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.